CCH Holdings Ltd Trading Halted Due to Volatility
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 12 2025
0mins
CCH Holdings Ltd trading halted, volatility trading pause
Get Free Real-Time Notifications for Any Stock
Monitor tickers like CCHH with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on CCHH
About CCHH
CCH Holdings Ltd is a specialty hotpot restaurant chains in Malaysia, specializing in chicken hotpot and fish head hotpot. The Company offers catering services in Malaysia and outside Malaysia mainly under two brands, namely Chicken Claypot House for its chicken hotpot restaurants and Zi Wei Yuan for its fish head hotpot restaurants through a combination of restaurant outlets and franchised restaurant outlets. The Company operates or licenses approximately 32 restaurant outlets, among which there are 20 Chicken Claypot House restaurant outlets, four Zi Wei Yuan restaurant outlets, three Chicken Claypot House-Zi Wei Yuan cross-over restaurant outlets, three restaurant outlets under the brand Bibixian focusing on Teochew-style chicken hotpot, a food court, and a restaurant outlet under the brand Banbudian Bistro offering Sichuan cuisine. It also has over four franchised restaurant outlets located in three other countries, including Thailand, Indonesia and China.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rapt Therapeutics Acquired by GSK for $58 per Share, Valuing at $2.2 Billion
- Acquisition Deal: GSK has agreed to acquire Rapt Therapeutics for $58 per share, representing an estimated total equity value of $2.2 billion, which will significantly enhance GSK's market position in the biopharmaceutical sector.
- Stock Surge: Rapt Therapeutics' shares jumped 63.4% to $57.36 in pre-market trading, reflecting a positive market reaction to the acquisition, which may attract more investor interest in the company.
- Market Impact: This acquisition not only increases shareholder value for Rapt but may also prompt other biotech firms to consider similar strategic acquisitions to enhance their competitiveness and market share.
- Industry Outlook: With GSK's acquisition, Rapt's product development process is expected to accelerate, potentially leading to faster drug launches and further solidifying GSK's leadership position in the innovative pharmaceuticals market.
Continue Reading
CCH Holdings Completes IPO Over-Allotment, Raising $750,000
- Successful Financing: CCH Holdings Ltd's underwriters fully exercised the over-allotment option in its IPO, purchasing an additional 187,500 ordinary shares, raising $750,000, which strengthens the company's capital base for future initiatives.
- Increased Total Proceeds: Following the over-allotment, CCH Holdings sold a total of 1,437,500 ordinary shares in the IPO, increasing total proceeds to $5.75 million, providing robust funding support for future expansion and operations.
- Market Performance: CCH Holdings' ordinary shares began trading on the Nasdaq Capital Market on October 3, 2025, marking a successful entry into the capital markets, which is expected to enhance brand visibility and attract more investor interest.
- Strategic Development: This financing will enable CCH Holdings to further expand its specialty hotpot market presence in Malaysia and Southeast Asia, enhancing its competitive edge and driving business growth.
Continue Reading